14 results about "Growth differentiation factor" patented technology

The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

The present invention relates to the use of at least one plant extract capable of activating GDF11 growth factor (Growth Differentiation Factor 11) for the treatment of hair growth, and to a cosmetic or pharmaceutical composition comprising at least one extract as an active ingredient for the treatment of hair growth. The at least one extract is selected from the group consisting of: a peptide and sugar enriched extract derived from a plant cell culture of scabrous raphanus; an extract rich in peptides and sugars derived from a lotus corniculatus plant cell culture rich in somatic embryos; an aqueous ethanol extract derived from artichoke flower heads; and / or a combination of a water soluble extract derived from Opuntia ficus stem nodes and a water ethanol extract derived from coffee beans.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and / or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and / or essential tremors are also disclosed.

The application discloses application of growth differentiation factor 15 in preparation of products for diagnosis, prognosis and treatment of retinal arterial obstruction, and finds that serum GDF15 level of a patient with RAO is greater than or equal to 442.64 pg / mL, and is significantly positively correlated with the risk of RAO (OR=12.6), and the diagnostic accuracy can be improved by combining glucose, triglyceride and other indexes (AUC=0.922). The recombinant human GDF15 protein can inhibit ischemia and hypoxia RGC apoptosis and protect visual function. The application has important application value in early diagnosis of RAO, visual prognosis evaluation and targeted treatment.

Provided in the present invention is an antibody or fragment thereof against a human growth and differentiation factor 15 protein (GDF15). Further provided in the present invention is the use of the antibody or fragment thereof in the preparation of a drug for treating diseases or conditions. The antibody or fragment thereof provided in the present invention can bind to human GDF15 with high affinity and specificity, blocks the interaction of GDF15 with receptor GFRAL thereof, and has a longer half-life period in vivo in comparison with antibodies of the same kind.

This disclosure provides combination therapy with GDF15 molecules. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, wherein a GDF15 region is fused to an Fc region, optionally via a linker. In one embodiment, the combination therapy comprises the administration of a GDF15 molecule with a GLP-1R agonist. In another embodiment, the combination therapy comprises the administration of a GDF15 molecule with a GIPR antagonist.

The embodiment of the invention discloses application of a growth differentiation factor 15 in preparation of a product for treating retinal artery occlusion. In-vitro and in-vivo experiments prove that the GDF15 has the potential of directly treating RAO: in an ischemia and hypoxia R28 cell model, the cell activity can be remarkably improved and apoptosis can be inhibited by the treatment of the recombinant human GDF15 protein. In an RAO mouse model, the GDF15 treatment can promote the survival of retinal ganglion cells and increase the thickness of a nerve fiber layer, and shows a clear eyesight protection effect. The product preferably contains recombinant human GDF15 protein, can inhibit cell death paths caused by ischemia and hypoxia in a targeted manner, and improves pathological changes such as retinal endoedema and tissue atrophy. The invention discloses the direct application of GDF15 as a therapeutic agent in RAO for the first time, provides an experimental basis for developing related drugs, and has important clinical application value in the field of ophthalmic emergency treatment.

The invention provides a GDF-15 (growth differentiation factor-15) magnetic particle chemiluminescence immunoassay quantitative detection kit, which belongs to the field of in vitro diagnosis, and comprises a magnetic particle suspension, a biotin-labeled GDF-15 capture antibody solution, an alkaline phosphatase-labeled GDF-15 detection antibody solution, a calibrator, a chemiluminescence solution and the like. The kit provided by the invention has the advantages of rapidness and simplicity in operation, high sensitivity and repeatability, large measurement range and good stability, and can make up for the defects of the existing detection method.

The application belongs to the technical field of antigen protein and antibody preparation and discloses a Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody, antigen protein and a preparation method thereof. The application obtains recombinant expression of the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein, obtains the Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody after immunizing mice, and provides an advantageous tool for the research on the Linopneus Genomic Differentiation Factor-8 / 11 protein level. The application also successfully obtains a Linopneus Genomic Differentiation Factor-8 / 11 antigen protein recombinant expression vector, and can obtain the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein. The application also provides a Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence, fills the blank of related research, and the primer pair provided by the application can amplify the above Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence through PCR, and can be used for other related research.

The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

To solve the problem that, to date, many cancers are still areas of unmet medical needs, and accordingly, means to more effectively treat cancer are needed.SOLUTION: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in treatment of solid cancers.SELECTED DRAWING: None

The invention relates to a method for producing cartilage from pluripotent stem cells (PSCs), the method comprising providing chondrocytes by: 1) providing pluripotent stem cells (PSCs); 2) inducing differentiation of the PSCs into a primitive streak / mesendoderm by culturing the PSCs in hypoxic conditions, in a (mesendodermic) culture media comprising: i) a Wingless / Integrated (WNT) family member, ii) an Activin family member, and iii) a Fibroblast Growth Factor (FGF) family member; 3) inducing differentiation of the primitive streak / mesendoderm into a mesoderm by culturing the primitive streak / mesendoderm in hypoxic conditions, in a (mesodermic) culture media comprising: i) a FGF family member, ii) a bone morphogenetic protein (BMP) family member, iii) Follistatin, and iv) a Neurotrophin (NT); and 4) inducing differentiation of the mesoderm into chondrocytes by culturing the mesoderm in hypoxic conditions, in a (chondroinductive) culture media comprising: i) a FGF family member, ii) a BMP family member, iii) a Neurotrophin, and iv) a Growth / Differentiation Factor (GDF) family member; and forming a pellet of the chondrocytes and culturing the pellet of the chondrocytes in a culture media under hypoxic conditions to produce the cartilage. The invention further relates to methods of chondrocyte production, synthetically produced cartilage, and use in therapy.